Aytu BioPharma, Inc. (NASDAQ:AYTU) is considered one of the best high-return penny stocks to buy now, with Lake Street Capital Markets initiating coverage with a Buy rating and $8.00 price target after its acquisition of EXXUA. The unique mechanism of its antidepressant is expected to boost revenue significantly by FY 2027, giving Aytu a competitive edge in the market. AYTU develops and commercializes innovative therapies, including ADHD treatments and pediatric medications. While AYTU shows potential as an investment, other AI stocks may offer greater upside potential and less downside risk.

Read more at Yahoo Finance: Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition